The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

The submission for treating paediatric plaque psoriasis is supported by outcomes from the Phase III PROTOSTAR study in ...

Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food ...

Helena has extensive experience in finance and business management,... at 04:44 InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...

3, 2024 /PRNewswire/ -- InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Johnson & Johnson announced the submission of two supplemental Biologics License Applications, sBLAs, to the U.S. Food and Drug ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...